autologous anti-gp 100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00509496)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanocyte protein PMELImmunity, passive
PMEL immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous anti-gp 100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00509496 | Phase 2 | Jun 1, 2007 | National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1